Drugs / ES102
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04991506 | Oct 2021 → May 2024 | cancer | Elpiscience Biopharma, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04730843 | Apr 2021 → Mar 2024 | cancer | Elpiscience Biopharma, Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06623136 | Apr 2025 → Feb 2027 expected | non-small cell lung carcinoma | Elpiscience (Suzhou) Biopharma, Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-05-18 | Elpiscience Biopharma, Ltd. | Results Interim Phase 2 Data for Hexavalent OX40 Agonist Combination Therapy in First-Line HNSCC Demonstrate Potential Benefit Over PD-1 Monotherapy elpiscience.com ↗
Data showed that ES102 in combination with Toripalimab demonstrated promising anti-tumor activity and synergistic effects in advanced solid tumors. |
| 2021-06-25 | Elpiscience Biopharma, Ltd. | Regulatory Elpiscience Announces CDE Clearance of IND Application for ES102 in Combination of Toripalimab elpiscience.com ↗
the Center of Drug Evaluation (CDE) has approved the IND application for ES102, a next generation anti-OX40 antibody, in combination with toripalimab (TUOYI®) an anti-PD1 antibody, in patients with advanced solid tumor. |
| 2020-06-15 | Elpiscience Biopharma, Ltd. | Regulatory Elpiscience Announces IND Submission of ES102 elpiscience.com ↗
it has submitted an Investigational New Drug (IND) application to the Center of Drug Evaluation (CDE) in Beijing to support the initiation of a Phase I clinical trial of ES102 in China. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-18 | Elpiscience Biopharma, Ltd. | Interim Phase 2 Data for Hexavalent OX40 Agonist Combination Therapy in First-Line HNSCC Demonstrate Potential Benefit Over PD-1 Monotherapy elpiscience.com ↗ |
| 2021-10-15 | Elpiscience Biopharma, Ltd. | Elpiscience Announces First Patient Dosed with ES102 in combination with Toripalimab in China elpiscience.com ↗ |
| 2021-06-25 | Elpiscience Biopharma, Ltd. | Elpiscience Announces CDE Clearance of IND Application for ES102 in Combination of Toripalimab elpiscience.com ↗ |
| 2020-06-15 | Elpiscience Biopharma, Ltd. | Elpiscience Announces IND Submission of ES102 elpiscience.com ↗ |
| 2018-05-01 | Elpiscience Biopharma, Ltd. | Elpiscience and Inhibrx Announce an Exclusive Collaboration and License Agreement of INBRX-106 (ES102) in Greater China elpiscience.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ES102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06623136 ↗ |
| Action | Activate | “ES102 (OX40 Agonist)” NCT04730843 ↗ |
| Route | Intravenous | “ES102 is administered via intravenous injection once every 21 days” NCT04730843 ↗ |
| Target | TNFRSF4 | “targets the human OX40 receptor (TNFRSF4)” NCT04991506 ↗ |